We have tested multiple immunocompromised strains in support of our patient PBMC growth to settle upon the use of unconditioned NSG (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ) mice as balanced against closely monitored GVHD (34), which provided a very workable window of treatment of 45-50 days. Here, CTSG is linked to graft versus host disease.